<DOC>
	<DOCNO>NCT00710606</DOCNO>
	<brief_summary>There 60 million woman reproductive age U.S. majority woman qualify overweight obese . Evidence suggest association increase body weight decrease contraceptive efficacy . Studies combine hormonal contraceptive patch ( Evra® ) subdermal contraceptive implant ( Norplant® ) demonstrate high failure rate heavier versus light woman . Weight related difference effectiveness NuvaRing® need study . A single secondary analysis pool data Phase III clinical trial NuvaRing® note difference pregnancy rate among woman high weight decile ( &gt; 166 # ) versus rest study population use ring . ( Westhoff , 2005 ) The finding difference , however , influence obese subject analysis contribute wide confidence limit . Additional study need explore well contraceptive ring function maintain effective serum steroid concentration suppress ovarian activity obese woman . This investigation focus evaluate mean serum concentration hormone release obese normal weight woman use NuvaRing® . This study prospective clinical trial . Normal weight woman define woman BMI 19-24.9 obese woman BMI 30-39.9 . We recruit forty adult woman interested initiating combine hormonal contraceptive ring two month use complete analysis least 34 subject ( 17 normal weight , 17 obese ) . We compare mean serum concentration ethinyl estradiol ( E2 ) etonogestrel ( ENG ) along additional marker ovarian suppression . These marker include sonographic evidence follicular development ovulation well circulate E2 level strongly correlate follicular development endometrial proliferation second month NuvaRing® use . Assessment parameter translate understanding contraceptive-mediated suppression ovarian function two group . Subjects also log pattern ring use bleeding pattern study period .</brief_summary>
	<brief_title>Comparison Serum Contraceptive Hormone Levels Between Normal Weight Obese Users NuvaRing®</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>1835 yo Meet BMI requirement Weight stable English speaking Desire contraception History regular menses normal uterus ovary Medically eligible combine hormonal contraception Tolerates phlebotomy/TVS Exclusion : Heavy smoker Users medication alter hormone level</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>contraceptive ring</keyword>
	<keyword>obesity</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Pharmacokinetics contraceptive ring obese woman .</keyword>
</DOC>